ScaleReady Announces a G-Rex® Grant has been awarded to Xellera Therapeutics. ST. PAUL, Minn., 6 August, 2025
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, today announced that Xellera Therapeutics has been awarded a US$150,000 G-Rex® Grant to support the establishment of a highly efficient cGMP G-Rex® centric NK cell manufacturing platform NK cell therapies represent a rapidly growing segment in immuno-oncology, offering off-the-shelf treatment options for a wide range of solid tumors, hematologic malignancies, and viral infections.